Q1 Earnings Forecast for HALO Issued By Leerink Partnrs

Halozyme Therapeutics, Inc. (NASDAQ:HALO) – Leerink Partnrs issued their Q1 2025 earnings estimates for shares of Halozyme Therapeutics in a report released on Sunday, January 12th. Leerink Partnrs analyst D. Risinger expects that the biopharmaceutical company will earn $0.93 per share for the quarter. The consensus estimate for Halozyme Therapeutics’ current full-year earnings is $3.80 per share. Leerink Partnrs also issued estimates for Halozyme Therapeutics’ Q2 2025 earnings at $1.04 EPS, Q3 2025 earnings at $1.41 EPS and FY2029 earnings at $8.16 EPS.

Several other research analysts have also recently issued reports on the stock. JPMorgan Chase & Co. cut shares of Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and raised their target price for the stock from $52.00 to $57.00 in a report on Thursday, September 19th. JMP Securities raised their target price on Halozyme Therapeutics from $72.00 to $73.00 and gave the stock a “market outperform” rating in a research note on Friday, November 1st. Piper Sandler upped their price target on Halozyme Therapeutics from $52.00 to $53.00 and gave the company a “neutral” rating in a research report on Friday, January 10th. Cowen reissued a “buy” rating on shares of Halozyme Therapeutics in a research note on Friday, October 18th. Finally, Wells Fargo & Company decreased their target price on Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating for the company in a report on Monday. Four analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $60.89.

Halozyme Therapeutics Stock Down 0.6 %

HALO opened at $53.83 on Tuesday. The company has a market cap of $6.85 billion, a P/E ratio of 17.82, a P/E/G ratio of 0.44 and a beta of 1.24. Halozyme Therapeutics has a 12 month low of $33.15 and a 12 month high of $65.53. The business’s 50-day moving average price is $50.05 and its 200-day moving average price is $54.05. The company has a current ratio of 10.36, a quick ratio of 9.15 and a debt-to-equity ratio of 3.32.

Insider Activity at Halozyme Therapeutics

In other Halozyme Therapeutics news, Director Jeffrey William Henderson sold 10,000 shares of Halozyme Therapeutics stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $50.01, for a total value of $500,100.00. Following the completion of the sale, the director now owns 43,611 shares of the company’s stock, valued at approximately $2,180,986.11. The trade was a 18.65 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 2.40% of the stock is currently owned by insiders.

Institutional Trading of Halozyme Therapeutics

A number of hedge funds have recently bought and sold shares of HALO. Argent Capital Management LLC increased its position in shares of Halozyme Therapeutics by 35.1% during the 4th quarter. Argent Capital Management LLC now owns 12,841 shares of the biopharmaceutical company’s stock valued at $614,000 after purchasing an additional 3,339 shares during the last quarter. Outlook Wealth Advisors LLC purchased a new stake in Halozyme Therapeutics in the fourth quarter worth about $355,000. Redhawk Wealth Advisors Inc. lifted its position in shares of Halozyme Therapeutics by 3.4% during the 4th quarter. Redhawk Wealth Advisors Inc. now owns 38,035 shares of the biopharmaceutical company’s stock valued at $1,818,000 after buying an additional 1,267 shares in the last quarter. Park Avenue Securities LLC grew its stake in shares of Halozyme Therapeutics by 6.9% during the 4th quarter. Park Avenue Securities LLC now owns 12,439 shares of the biopharmaceutical company’s stock valued at $595,000 after acquiring an additional 801 shares during the period. Finally, Tealwood Asset Management Inc. raised its stake in Halozyme Therapeutics by 19.7% during the 4th quarter. Tealwood Asset Management Inc. now owns 52,813 shares of the biopharmaceutical company’s stock worth $2,525,000 after acquiring an additional 8,694 shares during the period. Hedge funds and other institutional investors own 97.79% of the company’s stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.